"sam gandy also endorsed dimebon. he is a media whore" Thats a bit harsh dont you think MLG. [Dr. Gandy is an international expert in the metabolism of the substance called amyloid that clogs the brain in patients with Alzheimer's. In 1989, Gandy and his team discovered the first drugs that could lower formation of amyloid. Dr. Gandy has written more than 150 original papers, chapters and reviews on this topic. Dr. Gandy has received continuous NIH funding for his research on amyloid metabolism since 1986. Dr. Gandy is Professor of Alzheimer's Disease Research, Professor of Neurology and Psychiatry, and Associate Director of the Mount Sinai Alzheimer's Disease Research Center, and Chair, National Medical and Scientific Advisory Council of the Alzheimer's Association.]
The late Mark Smith was scientific advisor for MDVN on Dimebon. He also became a strong supporter of PRAN's science. Sam Gandy has been in the media on many occasions, and has testified before congress on the subject more than once.
There is a reason for Gandys change of heart. [“Plaques are no longer where the action is,” notes Sam Gandy, M.D., researcher at the Mount Sinai School of Medicine in New York City. Gandy has showed, using specially genetically-engineered mice (mice that develop Alzheimer’s even though their brains are plaque-free), that it may be clumps of amyloid beta protein (“oligomers”) that cause Alzheimer’s, and that plaque may actually be the brain’s way of defending itself against oligomers (in the same way that oysters wrap grains of irritating sand in pearl coatings, notes Robert Tanzi, head of Genetics & Aging Research at Boston’s Mass General). In other words, plaque may be the brain’s ineffective solution to Alzheimer’s, not the cause.] http://timnovate.wordpress.com/sam-gandy-finding-the-real-cause-of-alzheimer%E2%80%99s/
Metal ions stimulate amyloid-beta to clump into its toxic form. Any compound that blocks that interaction would be predicted to be beneficial in delaying, preventing, or treating Alzheimer’s,” says Sam Gandy, MD, PhD, a professor of neurology and psychiatry and Mount Sinai chair in Alzheimer’s disease research at Mount Sinai School of Medicine.
MELBOURNE, Australia, April 1 /PRNewswire-FirstCall/ -- Prana Biotechnology (ASX:PBT; Nasdaq: PRAN) today announced that an independent study conducted by researchers at the University of California, Irvine, validates Prana's fundamental drug strategy for Alzheimer's Disease in blocking the toxic interaction between Abeta and brain metals, such as zinc, that damages synapses and cause cognitive loss.
The study, published in the Journal of Neuroscience showed that the release of zinc from synapses is critical for Abeta to form oligomers and to aggregate. Dr Glabe, an author of the paper, noted, "These results are very exciting news for understanding the mechanism of Alzheimer pathogenesis. They help elucidate the fundamental role of metal ions like zinc in causing the formation of Abeta oligomers which damage synapses". http://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/04-01-2009/0004998741&EDATE=
MLG, I could keep on posting links like this, but PRAN's methods are being accepted by many scientists, although so far not big pharma or the street. If all those scientists are wrong it would not be the first time. For some reason Prana is still almost under the radar but seems to be on a hair trigger. I know what a gut wrenching experience it is to have a large investment crash as ELN did. Do you think you can rely on Kelly Martin to pull ELN back up? It may be worth doing some unbiased DD on Prana.
Market Data 
Markets 
AI
